503 related articles for article (PubMed ID: 17652581)
21. Altered NMDA receptor trafficking in a yeast artificial chromosome transgenic mouse model of Huntington's disease.
Fan MM; Fernandes HB; Zhang LY; Hayden MR; Raymond LA
J Neurosci; 2007 Apr; 27(14):3768-79. PubMed ID: 17409241
[TBL] [Abstract][Full Text] [Related]
22. Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease.
Van Raamsdonk JM; Pearson J; Murphy Z; Hayden MR; Leavitt BR
BMC Neurosci; 2006 Dec; 7():80. PubMed ID: 17147801
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of TRPC1-Dependent Store-Operated Calcium Entry Improves Synaptic Stability and Motor Performance in a Mouse Model of Huntington's Disease.
Wu J; Ryskamp D; Birnbaumer L; Bezprozvanny I
J Huntingtons Dis; 2018; 7(1):35-50. PubMed ID: 29480205
[TBL] [Abstract][Full Text] [Related]
24. Endocannabinoid-Specific Impairment in Synaptic Plasticity in Striatum of Huntington's Disease Mouse Model.
Sepers MD; Smith-Dijak A; LeDue J; Kolodziejczyk K; Mackie K; Raymond LA
J Neurosci; 2018 Jan; 38(3):544-554. PubMed ID: 29192125
[TBL] [Abstract][Full Text] [Related]
25. Differential electrophysiological changes in striatal output neurons in Huntington's disease.
André VM; Cepeda C; Fisher YE; Huynh M; Bardakjian N; Singh S; Yang XW; Levine MS
J Neurosci; 2011 Jan; 31(4):1170-82. PubMed ID: 21273402
[TBL] [Abstract][Full Text] [Related]
26. Ex vivo delivery of GDNF maintains motor function and prevents neuronal loss in a transgenic mouse model of Huntington's disease.
Ebert AD; Barber AE; Heins BM; Svendsen CN
Exp Neurol; 2010 Jul; 224(1):155-62. PubMed ID: 20227407
[TBL] [Abstract][Full Text] [Related]
27. Inositol 1,4,5-tripshosphate receptor, calcium signalling and Huntington's disease.
Bezprozvanny I
Subcell Biochem; 2007; 45():323-35. PubMed ID: 18193642
[TBL] [Abstract][Full Text] [Related]
28. An automated and quantitative method to evaluate progression of striatal pathology in Huntington's disease transgenic mice.
Liang X; Wu J; Egorova P; Bezprozvanny I
J Huntingtons Dis; 2014; 3(4):343-350. PubMed ID: 25575955
[TBL] [Abstract][Full Text] [Related]
29. Unraveling a role for dopamine in Huntington's disease: the dual role of reactive oxygen species and D2 receptor stimulation.
Charvin D; Vanhoutte P; Pagès C; Borrelli E; Caboche J
Proc Natl Acad Sci U S A; 2005 Aug; 102(34):12218-23. PubMed ID: 16103364
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms of synaptic dysfunction and excitotoxicity in Huntington's disease.
Sepers MD; Raymond LA
Drug Discov Today; 2014 Jul; 19(7):990-6. PubMed ID: 24603212
[TBL] [Abstract][Full Text] [Related]
31. Striatal neurochemical changes in transgenic models of Huntington's disease.
Ariano MA; Aronin N; Difiglia M; Tagle DA; Sibley DR; Leavitt BR; Hayden MR; Levine MS
J Neurosci Res; 2002 Jun; 68(6):716-29. PubMed ID: 12111832
[TBL] [Abstract][Full Text] [Related]
32. Differential changes in thalamic and cortical excitatory synapses onto striatal spiny projection neurons in a Huntington disease mouse model.
Kolodziejczyk K; Raymond LA
Neurobiol Dis; 2016 Feb; 86():62-74. PubMed ID: 26621114
[TBL] [Abstract][Full Text] [Related]
33. BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice.
Xie Y; Hayden MR; Xu B
J Neurosci; 2010 Nov; 30(44):14708-18. PubMed ID: 21048129
[TBL] [Abstract][Full Text] [Related]
34. Pathway-Specific Control of Striatal Neuron Vulnerability by Corticostriatal Cannabinoid CB1 Receptors.
Ruiz-Calvo A; Maroto IB; Bajo-Grañeras R; Chiarlone A; Gaudioso Á; Ferrero JJ; Resel E; Sánchez-Prieto J; Rodríguez-Navarro JA; Marsicano G; Galve-Roperh I; Bellocchio L; Guzmán M
Cereb Cortex; 2018 Jan; 28(1):307-322. PubMed ID: 29121220
[TBL] [Abstract][Full Text] [Related]
35. Decreasing Levels of the cdk5 Activators, p25 and p35, Reduces Excitotoxicity in Striatal Neurons.
Park KH; Lu G; Fan J; Raymond LA; Leavitt BR
J Huntingtons Dis; 2012; 1(1):89-96. PubMed ID: 24353748
[TBL] [Abstract][Full Text] [Related]
36. Neuroanatomical Visualization of the Impaired Striatal Connectivity in Huntington's Disease Mouse Model.
Kim D; Jeon J; Cheong E; Kim DJ; Ryu H; Seo H; Kim YK
Mol Neurobiol; 2016 May; 53(4):2276-86. PubMed ID: 25976370
[TBL] [Abstract][Full Text] [Related]
37. Differential changes to D1 and D2 medium spiny neurons in the 12-month-old Q175+/- mouse model of Huntington's Disease.
Goodliffe JW; Song H; Rubakovic A; Chang W; Medalla M; Weaver CM; Luebke JI
PLoS One; 2018; 13(8):e0200626. PubMed ID: 30118496
[TBL] [Abstract][Full Text] [Related]
38. Interaction of postsynaptic density protein-95 with NMDA receptors influences excitotoxicity in the yeast artificial chromosome mouse model of Huntington's disease.
Fan J; Cowan CM; Zhang LY; Hayden MR; Raymond LA
J Neurosci; 2009 Sep; 29(35):10928-38. PubMed ID: 19726651
[TBL] [Abstract][Full Text] [Related]
39. Single-Nucleus RNA-Seq Reveals Dysregulation of Striatal Cell Identity Due to Huntington's Disease Mutations.
Malaiya S; Cortes-Gutierrez M; Herb BR; Coffey SR; Legg SRW; Cantle JP; Colantuoni C; Carroll JB; Ament SA
J Neurosci; 2021 Jun; 41(25):5534-5552. PubMed ID: 34011527
[TBL] [Abstract][Full Text] [Related]
40. p35 hemizygosity activates Akt but does not improve motor function in the YAC128 mouse model of Huntington's disease.
Park KHJ; Franciosi S; Parrant K; Lu G; Leavitt BR
Neuroscience; 2017 Jun; 352():79-87. PubMed ID: 28391013
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
